You are here: Industry Insights > Niclosamide

News List

NeuroBo Pharmaceuticals Announces Positive Recommendation from Independent Data Safety Monitoring Committee of Phase 2/3 Clinical Trial of ANA001 in Hospitalized Patients with Moderate to Severe COVID prnewswire
October 14, 2021
NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal disease-modifying therapies for viral, neuropathic and neurodegenerative diseases...
CSIR and Laxai Life Sciences begin phase II trial of niclosamide drug to treat COVID-19 expresspharma
June 08, 2021
Niclosamide has been extensively used in the past for treating tapeworm infection in adults as well as children.
Phase II clinical trial of Niclosamide drug for treatment of COVID-19 patients begins firstwordpharma
June 07, 2021
The Council for Scientific and Industrial Research (CSIR) and Laxai Life Sciences have initiated Phase II trials of the anti-helminitic drug niclosamide for the treatment of hospitalized COVID-19 patients, reported The Economic Times.
A 'Game Changer' COVID-19 drug from Korea was introduced in a world class academic journal prnasia
May 24, 2021
Hyundai Bioscience announced on the 24th that CNPharm, its major shareholding bio tech company, published an article containing the research results of CP-COV03, a Niclosamide-based oral treatment for COVID-19 based on its proprietary oral formulation ...
Hyundai Bioscience leads in the repurposing of Niclosamide prnasia
April 09, 2021
A research paper by a South Korean bio tech company that demonstrated the drug repurposing of Niclosamide, an anthelmintic known to have excellent therapeutic efficacy against novel coronavirus infection (COVID-19), was published in the world-renowned ...
Hyundai Bioscience announced that its COVID-19 oral drug solved Niclosamide's inhibitory concentration problem prnewswire
December 09, 2020
Hyundai Bioscience released a report on December 8th that CP-COV03, its new COVID-19 oral drug candidate, successfully demonstrated a 100% inhibitory concentration level in the blood (IC100) for 12 hours against viral activity with a single ...
ANA Therapeutics initiates trial of oral niclosamide for Covid-19 treatment pharmaceutical-technology
October 28, 2020
Biotech firm ANA Therapeutics has begun Phase II/III trial to analyse the safety and efficacy of its oral niclosamide (ANA001) formulation for treating patients with moderate Covid-19.
TFF Pharmaceuticals Signs Worldwide Licensing Agreement with Union Therapeutics contractpharma
August 18, 2020
Will develop dry powder forms of niclosamide as a potential COVID-19 treatment.
Daewoong finds niclosamide effective against Covid-19 in animal tests pharmaceutical-technology
June 11, 2020
South Korea-based Daewoong Pharmaceutical has found that its anti-parasitic drug niclosamide removed SARS-CoV-2, the novel coronavirus that causes Covid-19, from lungs in animal tests.
Niclosamide could lead the fight against Parkinson’s disease europeanpharmaceuticalreview
May 05, 2019
Drug molecule in tapeworm medicine activates protein implicated in the development of Parkinson’s disease…

Previous page 1 2 Next page